{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-124141","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2024-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.739486+00:00","generated_at":"2026-05-30T02:55:45.273741+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Revelation Biosciences reports Q3 net loss of $2.2M; cash $6.5M into 2025","bullets":["Net loss Q3 2024: $2.2M ($0.84 per share) vs $2.6M loss in Q3 2023; nine-month net loss $13.3M vs net income $2.1M in prior year.","Cash and cash equivalents $6.5M as of Sep 30, 2024, down from $12.0M at Dec 31, 2023; raised $3.8M from warrant exercise in Aug 2024.","Clinical-stage biotech advancing Gemini; expects FDA IND acceptance to start Phase 1b in CKD patients; cash runway into 2025.","Net cash used in operations nine months: $14.6M vs $5.3M in 2023; cash burn increased significantly."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-124141","json":"https://secwatch.observer/filing/0000950170-24-124141.json","markdown":"https://secwatch.observer/filing/0000950170-24-124141.md","text":"https://secwatch.observer/filing/0000950170-24-124141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024124141/0000950170-24-124141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024124141/revb-20241108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:55:45.273741+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}